Welcome to our dedicated page for Harpoon Therapeutics news (Ticker: HARP), a resource for investors and traders seeking the latest updates and insights on Harpoon Therapeutics stock.
Harpoon Therapeutics, Inc. (NASDAQ: HARP) is a clinical-stage immunotherapy company founded in 2015. Specializing in developing T cell engagers, Harpoon harnesses the body’s immune system to combat cancer and other serious diseases. Co-founded by Patrick Bauerle and Luke Evnin, the company leverages groundbreaking T cell recruiting antibodies to develop next-generation therapies. Harpoon's innovative platforms include the Tri-specific T cell Activating Construct (TriTAC®), ProTriTAC™, and TriTAC-XR. The TriTAC® platform aims to direct a patient's own immune cells to target and destroy tumor cells, primarily focusing on solid tumors and hematologic malignancies.
One of Harpoon's leading projects is HPN328, targeting delta-like ligand 3 (DLL3). Currently in a Phase 1/2 clinical trial, HPN328 shows promise in treating small cell lung cancer (SCLC) and other neuroendocrine tumors. Interim results indicate a 35% confirmed response rate in all tumor types studied, with higher efficacy observed in non-SCLC neuroendocrine tumors.
Harpoon's innovative approach extends to their proprietary ProTriTAC™ platform, which remains inactive until reaching the tumor, ensuring higher precision and reduced side effects. Additionally, the TriTAC-XR platform is designed to mitigate cytokine release syndrome, a common challenge in T cell therapies.
Financially, Harpoon has secured robust funding through recent PIPE financings, ensuring a solid runway into 2026. Strategic partnerships with leading oncology research centers and a strong focus on regulatory milestones underscore Harpoon's commitment to advancing cancer treatment. For more information, visit www.harpoontx.com.
- HPN328 received Orphan Drug Designation from the FDA in March 2022.
- The company is actively presenting data at major oncology conferences such as ESMO and ASCO-GU.
- Harpoon plans to meet with regulators in early 2024 to discuss further development plans for HPN328.
Harpoon Therapeutics (NASDAQ: HARP) announced its participation in a virtual fireside chat at the 11th Annual SVB Leerink Global Healthcare Conference. The event is scheduled for February 16, 2022, at 5 p.m. ET (2 p.m. PT). A live audio webcast will be available on the company's website, with an archived replay following the event.
Harpoon focuses on developing novel T cell engagers that employ the body’s immune system to treat cancer and other diseases. Their pipeline includes several therapies targeting specific cancer markers.
Harpoon Therapeutics (NASDAQ: HARP) announced a milestone update on its TriTAC development programs, commencing 2022 with significant clinical advancements. Key initiatives include advancing the HPN217 program to the next development phase and submitting the first IND for HPN601. Anticipated milestones for 2022 include dose escalations and the initiation of expansion cohorts for multiple candidates. Harpoon plans to host an R&D Day in the first half of the year, further emphasizing its commitment to developing novel T cell engagers for cancer treatment.
Sensorion (Euronext Paris: ALSEN) has appointed Scott D. Myers as Chairman of its Board of Directors, succeeding Edwin Moses who is stepping down on
Harpoon Therapeutics (HARP) announced promising interim results from ongoing Phase 1/2 clinical trials for its drug candidates HPN217 and HPN328. Notably, HPN217 demonstrated a 63% overall response rate (ORR) and an 88% disease control rate (DCR) among patients with relapsed/refractory multiple myeloma. In the HPN328 trial for small cell lung cancer, 75% of patients showed target lesion reduction, with one patient achieving a 53% reduction. Harpoon's pipeline continues to advance, with plans for an IND submission for HPN601 expected in late 2022.
Harpoon Therapeutics (NASDAQ: HARP) presented promising interim data from its ongoing Phase 1/2 trial on HPN217 for relapsed/refractory multiple myeloma at the ASH Annual Meeting. The results showed a63% overall response rate (ORR) and an88% disease control rate (DCR) in the 2150 µg/week cohort. Notably, 2 stringent complete responses were recorded. The treatment exhibited a tolerable safety profile, with cytokine release syndrome (CRS) reported in 24% of patients, all Grade 1 or 2. Ongoing patient enrollment aims to finalize the recommended Phase 2 dose.
Harpoon Therapeutics announced a conference call and webcast on December 13, 2021, at 4:30 p.m. ET to discuss its clinical status and pipeline programs. Investors can dial in at (866) 951-6894 for domestic calls or (409) 216-0624 internationally, using conference ID 2760075. The live event will also be accessible via the investor relations section of the Harpoon website. The company focuses on developing novel T cell engagers to treat cancer and other diseases, utilizing its proprietary TriTAC platform.
Harpoon Therapeutics (NASDAQ: HARP) revealed preclinical data for its TriTAC-XR T cell engager platform at the 36th Annual Meeting of the Society for Immunotherapy of Cancer. The data suggests that TriTAC-XR can mitigate cytokine release syndrome (CRS), a significant toxicity in T cell engagers. Studies in non-human primates showed that TriTAC-XR reduces peak cytokine levels while maintaining potency against FLT3-expressing cells. The company aims to explore its applications beyond oncology, showcasing a commitment to developing innovative immunotherapy solutions.
Harpoon Therapeutics (HARP) reported its Q3 2021 financial results with revenue at $4.5 million, up from $3.9 million in Q3 2020, driven by increased collaboration with AbbVie. The net loss for Q3 was $16.7 million, escalating to $95.2 million for the nine months ending September 30, 2021, largely due to a $50 million Maverick litigation settlement. Harpoon remains optimistic about its ongoing clinical trials and the launch of new platforms, including TriTAC-XR. Cash reserves increased slightly to $154.2 million, and 2021 operating expenses are projected to be below initial guidance.
Harpoon Therapeutics (NASDAQ: HARP) announced its participation in two upcoming virtual investor conferences. A fireside chat at Stifel’s 2021 Virtual Healthcare Conference is scheduled for November 15, 2021, at 4 p.m. ET, and a pre-recorded chat at Piper Sandler’s 33rd Annual Healthcare Conference will be available starting November 22, 2021. Harpoon will also conduct 1x1 investor meetings on November 30, 2021. Webcasts will be accessible on the company’s website following the events. Harpoon is focused on developing innovative T cell engagers for cancer treatment.
Harpoon Therapeutics (NASDAQ: HARP) has announced the acceptance of two abstracts for poster presentation at the 63rd American Society of Hematology (ASH) Annual Meeting, scheduled for December 11-14, 2021, in Atlanta, GA. The abstracts detail findings from studies on HPN217, a tri-specific T cell engager targeting B-cell maturation antigen for treating relapsed/refractory multiple myeloma. The presentations will occur on December 11, 2021, and will be accessible on the company's website afterward.
FAQ
What is the market cap of Harpoon Therapeutics (HARP)?
What is Harpoon Therapeutics' primary focus?
What is the TriTAC® platform?
What are the recent clinical trial updates for HPN328?
What does the ProTriTAC™ platform do?
What is the significance of TriTAC-XR?
What financial steps has Harpoon taken recently?
What is HPN328 targeting?
When did HPN328 receive Orphan Drug Designation?
Where can I find more information about Harpoon Therapeutics?
What are Harpoon’s plans for HPN328 in 2024?
